New research commissioned by Talker Research on behalf of Revance uncovers a striking knowledge gap in ingredient awareness. From skincare to supplements, Americans are paying closer attention than ever to the ingredients in the products they use. Yet that attentiveness drops when it comes to injectable frown line treatments—despite being one of the most popular aesthetic procedures in the U.S.—leaving many consumers unaware of key differences.
The national survey of 2,000 U.S. adults aged 30–54 revealed that:
- 91 percent of respondents are more ingredient-aware today than in the past.
- 61 percent of consumers say the top reason they research ingredients is to ensure a product works well, followed by managing allergies (41 percent) and understanding product differences (36 percent).
- 31 percent of respondents say AI tools have already helped them make smarter ingredient decisions.
While there is a notable increase in ingredient interest in other categories, a major blind spot remains for frown line treatments: fewer than half could recall any one ingredient in an available neurotoxin treatment on the market, and 53% mistakenly believe all formulations are “more or less the same”—despite significant differences. In fact, most respondents did not recognize that human or animal-based ingredients are common in many treatment formulations. “Consumers have become increasingly ingredient-savvy when it comes to what they put on and in their bodies and it’s time that same curiosity extends to aesthetic treatments,” says Jeff Bedard, founder and CEO of Revance. “Too often, frown line treatments get treated as if they’re all the same, when in reality there are meaningful differences in how they’re formulated. Most people already recognize peptides in skincare and wellness, but few realize there’s a neurotoxin formulated with a peptide.”